Allergen specific immunotherapy for atopic dermatitis

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 6, 2007, Pages 542-546

  Novak, Natalija ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Allergen specific tolerance; Atopic dermatitis; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

CORTICOSTEROID; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT;

ALLERGIC RHINITIS; ASTHMA; ATOPIC DERMATITIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DERMATOPHAGOIDES; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECZEMA; FLUSHING; HUMAN; IMMUNOTHERAPY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SCORING SYSTEM; SIDE EFFECT; SKIN SENSITIZATION; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CLINICAL TRIALS AS TOPIC; DERMATITIS, ATOPIC; HUMANS; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS;

EID: 35948946529     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282f1d66c     Document Type: Review

References (31)

1. Maintz L, Novak N. Getting more and more complex: the pathophysiology of atopic eczema. Eur J Dermatol 2007; 17:267-283.
2. Boguniewicz M, Leung DY. Atopic dermatitis. J Allergy Clin Immunol 2006; 117:S475-S480.
3. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-446.
4. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol 2006; 118:3-21.
5. Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006; 43:159-169.
6. FWeidinger S, Illig T, Barecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy Clin Immunol 2006; 118:214-219.
7. Kraft S, Kinet JP. New developments in FceRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365-378.
8. Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006; 118:178-189.
9. Park JH, Choi YL, Namkung JH, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. Br J Dermatol 2006; 155:778-783.
10. Kramer U, Lemmen C, Bartusel E, et al. Current eczema in children is related to Der f 1 exposure but not to Der p 1 exposure. Br J Dermatol 2006; 154:99-105.
11. Bohle B. The impact of pollen-related food allergens on pollen allergy. Allergy 2007; 62:3-10.
12. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006; 118:152-169.
13. Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006; 6:761-771. This paper nicely summarizes current knowledge about the mechanisms of allergen SIT.
14. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119:780-791.
15. Piconi S, Trabattoni D, Saresella M, et al. Effects of specific immunotherapy on the B7 family of costimulatory molecules in allergic inflammation. J Immunol 2007; 178:1931-1937.
16. Pilette C, Nouri-Aria KT, Jacobson MR, et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 2007; 178:4658-4666.
17. Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multicentre, randomized, dose-response study. Allergy 2006; 61:202-205. This is the most recent controlled study on allergen SIT in atopic dermatitis.
18. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120:164-170. This is the most recent controlled study on SLIT in atopic dermatitis.
19. Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes of atopic dermatitis patients undergoing subcutaneous allergen specific immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007; 37:1277-1285. This open-label study included monitoring of immunologic parameters during SIT in atopic dermatitis.
20. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy 1974; 32:321-330.
21. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet 1978; 2:912-915.
22. Ring J. Successful hyposensitization treatment in atopic eczema: results of a trial in monozygotic twins. Br J Dermatol 1982; 107:597-602.
23. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992; 22:440-446.
24. Leroy BP, Boden G, Lachapelle JM, et al. A novel therapy for atopic dermatitis with allergen-antibody complexes: a double-blind, placebo-controlled study. J Am Acad Dermatol 1993; 28:232-239.
25. Galli E, Chini L, Nardi S, et al. Use of a specific oral hyposensitization therapy to Dermatophagoides pteronyssinus in children with atopic dermatitis. Allergol Immunopathol (Madr) 1994; 22:18-22.
26. Noh GW, Lee KY. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 1998; 53:1202-1207.
27. Silny W, Czarnecka-Operacz M, Silny P. Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis. Part I. Evaluation of clinical score [in Polish]. Wiad Lek 2005; 58:47-55.
28. Silny W, Czarnecka-Operacz M. Specific immune therapy in the treatment of patients with atopic dermatitis [in German]. Allergologie 2006; 29:171-183. This controlled study included monitoring of immunologic parameters during SIT in atopic dermatitis.
29. Petrova SI, Berzhets VM, Al'banova VI, et al. Immunotherapy in the complex treatment of patients with atopic dermatitis with sensitization to house dust mites [in Russian]. Zh Mikrobiol Epidemiol Immunobiol 2001; (1):33-36.
30. Bussmann C, Bockenhoff A, Henke H, et al. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006; 118:1292-1298. This study contains a systematic review on all studies on SIT in atopic dermatitis conducted between 1974 and 2006.
31. Verhagen J, Akdis M, Traidl-Hoffmann C, et al. Absence of T-regulatory cell expression and function in atopic dermatitis skin. J Allergy Clin Immunol 2006; 117:176-183.